Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality J Elmén, H Thonberg, K Ljungberg, M Frieden, M Westergaard, Y Xu, ... Nucleic acids research 33 (1), 439-447, 2005 | 811 | 2005 |
Silencing of microRNA families by seed-targeting tiny LNAs S Obad, CO dos Santos, A Petri, M Heidenblad, O Broom, C Ruse, C Fu, ... Nature genetics 43 (4), 371-378, 2011 | 752 | 2011 |
Antisense drug technology: principles, strategies, and applications ST Crooke CRC press, 2007 | 624 | 2007 |
Solid‐phase synthesis of peptide nucleic acids L Christensen, R Fitzpatrick, B Gildea, KH Petersen, HF Hansen, T Koch, ... Journal of peptide science: an official publication of the European Peptide …, 1995 | 491 | 1995 |
Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents CA Stein, JB Hansen, J Lai, SJ Wu, A Voskresenskiy, A H⊘ g, J Worm, ... Nucleic acids research 38 (1), e3-e3, 2010 | 416 | 2010 |
Peptide nucleic acids: protocols and applications PE Nielsen Garland Science, 2004 | 396 | 2004 |
Short locked nucleic acid antisense oligonucleotides potently reduce apolipoprotein B mRNA and serum cholesterol in mice and non-human primates EM Straarup, N Fisker, M Hedtjärn, MW Lindholm, C Rosenbohm, ... Nucleic acids research 38 (20), 7100-7111, 2010 | 280 | 2010 |
PCSK9 LNA antisense oligonucleotides induce sustained reduction of LDL cholesterol in nonhuman primates MW Lindholm, J Elmén, N Fisker, HF Hansen, R Persson, MR Møller, ... Molecular therapy 20 (2), 376-381, 2012 | 216 | 2012 |
Locked nucleic acid: modality, diversity, and drug discovery PH Hagedorn, R Persson, ED Funder, N Albæk, SL Diemer, DJ Hansen, ... Drug Discovery Today 23 (1), 101-114, 2018 | 208 | 2018 |
Expanding the design horizon of antisense oligonucleotides with alpha‐l‐LNA M Frieden, SM Christensen, ND Mikkelsen, C Rosenbohm, CA Thrue, ... Nucleic acids research 31 (21), 6365-6372, 2003 | 171 | 2003 |
Stopped-flow kinetics of locked nucleic acid (LNA)–oligonucleotide duplex formation: studies of LNA–DNA and DNA–DNA interactions U CHRISTENSEN, N JACOBSEN, VK RAJWANSHI, J WENGEL, T KOCH Biochemical Journal 354 (3), 481-484, 2001 | 140 | 2001 |
Detection of the factor V Leiden mutation by direct allele-specific hybridization of PCR amplicons to photoimmobilized locked nucleic acids H Ørum, MH Jakobsen, T Koch, J Vuust, MB Borre Clinical chemistry 45 (11), 1898-1905, 1999 | 138 | 1999 |
Improvements in automated PNA synthesis using Boc/Z monomers T Koch, HF HANSEN, P ANDERSEN, T LARSEN, HG BATZ, K OTTESON, ... The Journal of peptide research 49 (1), 80-88, 1997 | 128 | 1997 |
Biological activity and biotechnological aspects of locked nucleic acids KE Lundin, T Højland, BR Hansen, R Persson, JB Bramsen, J Kjems, ... Advances in genetics 82, 47-107, 2013 | 123 | 2013 |
SPC3042: a proapoptotic survivin inhibitor JB Hansen, N Fisker, M Westergaard, LS Kjærulff, HF Hansen, CA Thrue, ... Molecular cancer therapeutics 7 (9), 2736-2745, 2008 | 121 | 2008 |
Knockdown of survivin (BIRC5) causes apoptosis in neuroblastoma via mitotic catastrophe F Lamers, I Van Der Ploeg, L Schild, ME Ebus, J Koster, BR Hansen, ... Endocrine Related Cancer 18 (6), 657, 2011 | 109 | 2011 |
On the in vitro and in vivo properties of four locked nucleic acid nucleotides incorporated into an anti‐H‐Ras antisense oligonucleotide K Fluiter, M Frieden, J Vreijling, C Rosenbohm, MB De Wissel, ... ChemBioChem 6 (6), 1104-1109, 2005 | 106 | 2005 |
Hepatotoxic potential of therapeutic oligonucleotides can be predicted from their sequence and modification pattern PH Hagedorn, V Yakimov, S Ottosen, S Kammler, NF Nielsen, AM Høg, ... nucleic acid therapeutics 23 (5), 302-310, 2013 | 103 | 2013 |
Targeting RNA with conformationally restricted oligonucleotides P Herdewijn Liebigs Annalen 1996 (9), 1337-1348, 1996 | 103 | 1996 |
Nuclease stability of LNA oligonucleotides and LNA-DNA chimeras M Frieden, HF Hansen, T Koch Nucleosides, Nucleotides and Nucleic Acids 22 (5-8), 1041-1043, 2003 | 95 | 2003 |